Littérature scientifique sur le sujet « Abstract Targeted radionuclide therapy (TRT) »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Abstract Targeted radionuclide therapy (TRT) ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Abstract Targeted radionuclide therapy (TRT)"
Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers et al. « Abstract 6407 : Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.
Texte intégralKerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin et al. « Abstract 2828 : Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.
Texte intégralPal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, Brian Sanders, Anna Plechaty, Owee Kirpekar, Mircea Podar et Sandra M. Davern. « Abstract 480 : Nanotherapeutic strategies to improve targeted radionuclide therapy ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.
Texte intégralAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan M. Minnix et al. « Abstract 2732 : A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy ». Cancer Research 82, no 12_Supplement (15 juin 2022) : 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.
Texte intégralKerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, David Adam, Maria Powers et al. « Abstract 1306 : Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models ». Cancer Research 82, no 12_Supplement (15 juin 2022) : 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.
Texte intégralAdhikarla, Vikram, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jeffrey Y. Wong et al. « Abstract 7374 : Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.
Texte intégralRuder, Samuel, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos et al. « Abstract 7582 : Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT) ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.
Texte intégralSheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, Joseph J. Grudzinski, David Adam, Maria Powers, Raghava N. Sriramaneni et al. « Abstract 6117 : Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.
Texte intégralVorontsova, M., T. Karmakova, A. Pankratov et A. Kaprin. « Current Trends in Targeted Radionuclide Therapy Development ». Medical Radiology and radiation safety 66, no 6 (17 décembre 2021) : 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.
Texte intégralvan der Wal, Bart C. H., et Ekaterina Dadachova. « Targeted Radionuclide Therapy of Cancer and Infections ». International Journal of Molecular Sciences 24, no 10 (22 mai 2023) : 9081. http://dx.doi.org/10.3390/ijms24109081.
Texte intégralThèses sur le sujet "Abstract Targeted radionuclide therapy (TRT)"
Rouanet, Jacques. « Radiothérapie interne du mélanome métastatique pigmenté : mécanismes et associations ». Electronic Thesis or Diss., Université Clermont Auvergne (2017-2020), 2019. http://www.theses.fr/2019CLFAS033.
Texte intégralTargeted radionuclide therapy (TRT) is a therapeutic strategy which consists in specificallyaddressing a radionuclide to tumor by targeting, through a specific vector. For melanoma TRT,the vector could be an antibody targeting surface antigens or melanin, a peptidomimetic ableto bind to receptors (i.e. the melanocyte-stimulating hormone receptor) or some smallmolecules which specifically bind to melanin (benzamides). Our research is focused on the latterclass with the lead molecule [ 131 I]ICF01012 developed in our unit for 15 years. Promisingpreclinical studies have resulted in a phase I clinical trial, MELRIV1, opened since July 2019(NCT03784625). In line with this trial, we pursued the preclinical characterization of [ 131 I]ICF01012effects in monotherapy and in combination with current melanoma treatments.We then defined two main axes:1) [ 131 I]ICF01012 impact on main mechanisms involved in melanomagenesis: metastaticdissemination and epithelial-mesenchymal-like transition, activation of the MAPK pathway andescape from anti-tumor immune response;2) [ 131 I]ICF01012 combination with current treatments: potential benefit assessmentIn the first axis, we developed a spheroid model and showed that [ 131 I]ICF01012 alteredthe expression of genes and proteins involved in pTEM and could therefore limit metastaticdissemination. These modifications brought also melanoma cell differentiation and induction ofpigmentation. Importantly, we showed the efficiency of [ 131 I]ICF01012 on metastaticdissemination by hematogenous route, targeting circulating cancer cells, and by lymphaticroute, decreasing number of lymph node metastases. We also demonstrated in vitro and in vivothe very high radiosensitivity of Q61K mutated NRAS 1007 cells. We also demonstrated, in themutated BRAF and NRAS spheroids, an activation of the MAPK pathway following TRT irradiation,traducing radioresistance appearance.For the second part, combination of TRT with MEK inhibitors in the spheroid modeldemonstrated the possibility of using these molecules to radiosensitize melanoma cells withconstitutional activation of the MAPK pathway. This radiosensitization lead to a major increase ofapoptosis. In the B16F10 syngeneic mouse model, we showed that TRT immune effects rely onimmunogenic cell death initiation, leading to adaptive immune response and cytotoxic T cellrecruitment. These mechanisms come with recruitment of regulatory T-cells which can contributeto tumor escape from immune response. Combination of TRT with immune checkpoint inhibitorsevidenced that immunological tolerance was a major induced mechanism following[ 131 I]ICF01012 irradiation while T-cell exhaustion appeared as a minor phenomenon. In addition,we were able to show that the reduction of immunological tolerance by an anti-CTLA-4antibody increases T-cell exhaustion. Furthermore, TRT combined with immune checkpointinhibitors, especially with anti-CTLA-4, led to a significant increase of survival compared tomonotherapies, with no increase of toxicity.Taken together, these results confirm the potential role of TRT using [ 131 I]ICF01012 in themanagement of metastatic melanoma. Notably, association with inhibitors of checkpointsinhibitors appears to be very promising for further clinical trials following the Phase I trial of[ 131 I]ICF01012
Chapitres de livres sur le sujet "Abstract Targeted radionuclide therapy (TRT)"
« Monoclonal antibody targeted radionuclide therapy ». Dans Targeted Therapy for Cancer, sous la direction de Surinder K. Batra, Apollina Goet Gabriela Pavlinkova et David Colcher, 57–75. Oxford University PressOxford, 2003. http://dx.doi.org/10.1093/oso/9780198508960.003.0005.
Texte intégralSharma, Vipasha, Suman Khurana, Mukesh Rani, Arun Mittal et Parveen Kumar Goyal. « RADIOPHARMACEUTICALS ». Dans Futuristic Trends in Pharmacy & ; Nursing Volume 3 Book 20, 59–78. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bgpn20p2ch3.
Texte intégralBhandare, Manish S., Vikas Gupta, Vikram A. Chaudhari et Shailesh V. Shrikhande. « Neuroendocrine Tumours of the Pancreas ». Dans Pancreas, sous la direction de Shailesh V. Shrikhande, Markus W. Büchler, Samiran Nundy et Dirk J. Gouma, 87—C11.P151. Oxford University PressOxford, 2022. http://dx.doi.org/10.1093/med/9780192858443.003.0011.
Texte intégralBharati, Dr Deepak, Prajwal Bari, Sakshi Nirhali, Jishaan Alam Khan et Pratiksha Umale. « RADIOPHARMACEUTICAL SCIENCE ». Dans Futuristic Trends in Pharmacy & ; Nursing Volume 3 Book 12, 193–249. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bgpn12p5ch4.
Texte intégralActes de conférences sur le sujet "Abstract Targeted radionuclide therapy (TRT)"
Gill, Martin R., Jyothi U. Menon, Robert Carlisle et Katherine A. Vallis. « Abstract 994 : Combining ruthenium metallo-intercalators and targeted radionuclide therapy for EGFR-overexpressing oesophageal cancer ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-994.
Texte intégralGill, Martin R., Jyothi U. Menon, Robert Carlisle et Katherine A. Vallis. « Abstract 994 : Combining ruthenium metallo-intercalators and targeted radionuclide therapy for EGFR-overexpressing oesophageal cancer ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-994.
Texte intégralJensen, Mette Munk, Jesper Fonslet, Camilla S. Knudsen, Troels E. Jeppesen, Andreas I. Jensen, Gregory W. Severin, Carsten H. Nielsen et Andreas Kjær. « Abstract 5203 : Tissue factor targeted radionuclide therapy with177Lu-FVIIai inhibits tumor growth of human pancreatic cancer xenografts ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5203.
Texte intégralJagodinsky, Justin C., Ian S. Arthur, Juliana S. Castillo, Ishan Chakravarty, Luke M. Zangl, Ryan J. Brown, Ravi B. Patel et al. « Abstract 477 : Comparing type 1 interferon activation in tumor cells following external beam radiotherapy versus targeted radionuclide therapy ». Dans Proceedings : AACR Annual Meeting 2020 ; April 27-28, 2020 and June 22-24, 2020 ; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-477.
Texte intégralSun, Michael, Muhammad Niaz, Charlene Thomas, Ariel Schaap, Kristine Lacuna, Panagiotis Vlachostergios, Paul Christos et al. « Abstract 6511 : Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy ». Dans Proceedings : AACR Annual Meeting 2020 ; April 27-28, 2020 and June 22-24, 2020 ; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6511.
Texte intégralJagodinsky, Justin C., Amber M. Bates, Reinier Hernandez, Joseph J. Grudzinski, Ian R. Marsh, Ishan Chakravarty, Ian S. Arthur et al. « Abstract 3060 : Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-3060.
Texte intégralPotluri, Hemanth Kumar, Reinier Hernandez, Christopher D. Zahm, Joseph Grudzinski, Christopher Massey, Jamey Weichert et Douglas G. McNeel. « Abstract 2262 : Low-dose targeted radionuclide therapy has favorable local and systemic effects on immune populations in a murine prostate cancer model ». Dans Proceedings : AACR Annual Meeting 2020 ; April 27-28, 2020 and June 22-24, 2020 ; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2262.
Texte intégralSosa, Gustavo A., Amber M. Bates, Ravi Patel, Reinier Hernandez, Joseph J. Grudzinski, Ian Marsh, Bryan Bednarz et al. « Abstract 903:In vivoefficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer ». Dans Proceedings : AACR Annual Meeting 2020 ; April 27-28, 2020 and June 22-24, 2020 ; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-903.
Texte intégralKwan, Tanya T., Minh Nguyen, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Matthias Paschke, Christian Haase et al. « Abstract LBA032 : Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286 ». Dans Abstracts : AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics ; October 7-10, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1535-7163.targ-21-lba032.
Texte intégralEmma, Sarah E., Amber M. Bates, Reinier Hernandez, Joseph J. Grudzinski, Ian R. Marsh, Justin C. Jagodinsky, Bryan P. Bednarz et al. « Abstract 508 : Mechanisms of cooperative response to bempegaldesleukin (BEMPEG) and90Y-NM600 targeted radionuclide therapy in the treatment of a syngeneic murine model of head and neck squamous cell carcinoma ». Dans Proceedings : AACR Annual Meeting 2021 ; April 10-15, 2021 and May 17-21, 2021 ; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-508.
Texte intégral